Related Experiment Video
Updated: Mar 17, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Glioblastoma multiforme targeted therapy: The Chlorotoxin story
Or Cohen-Inbar1, Menashe Zaaroor2
1Department of Neurological Surgery, Rambam Health Care Center, Haifa, Israel; Molecular Immunology Laboratory, Technion Israel Institute of Technology, Haifa, Israel; Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel; Department of Neurological Surgery and Gamma-Knife Radiosurgical Center, University of Virginia Health Care Centre, 1215 Lee St, Charlottesville, VA 22908, USA.
Abstract:
Glioblastoma multiforme (GBM) is the most common malignant primary brain neoplasm having a mean survival of <24months. Scorpion toxins are considered promising cancer drug candidates, primarily due to the discovery of hlorotoxin, derived from the venom of the Israeli yellow scorpion. This intriguing short peptide of only 36 amino-acids length and tight configuration, possess the ability to bind to GBM cells in a grade-related manner with ∼100% of GBM cells staining positive and no cross reactivity to normal brain. Chlorotoxin has an anti-angiogenic effect as well. Molecular targets for Chlorotoxin include voltage gated chloride channels (GCC), calcium-dependent phospholipid-binding protein Annexin-2, and the inducible extracellular enzyme Matrix Metalloproteinase-2 (MMP-2). Of all its targets, MMP-2 seems to bear the most anti-neoplastic potential. Chlorotoxin is a promising tumortargeting peptide. Its small size and compact shape are convenient for intracranial delivery. We present a short discussion on Chlorotoxin. The structure, biological activity, molecular targets and possible clinical role of Chlorotoxin are discussed. Chlorotoxin can be utilized as a targeting domain as well, attaching different effector functions to it. Clinical applications in GBM therapy, intraoperative imaging, nano-probes and nano-vectors based technology; targeted chemotherapy and immunotherapy are discussed as well. Chlorotoxin is likely to play a significant role in effective GBM immunotherapy in the future.
Insights
Chlorotoxin, a peptide from scorpion venom, shows high specificity for glioblastoma multiforme (GBM) cells. This promising compound targets GBM, offering potential for novel brain cancer therapies.
Area of Science:
- Neuro-oncology
- Peptide Therapeutics
- Venom-derived Compounds
Background:
- Glioblastoma multiforme (GBM) is an aggressive primary brain tumor with a poor prognosis.
- Scorpion venom contains peptides with potential anti-cancer properties, notably chlorotoxin.
Purpose of the Study:
- To discuss the structure, biological activity, and molecular targets of chlorotoxin.
- To explore the potential clinical applications of chlorotoxin in glioblastoma therapy.
Main Methods:
- Review of existing literature on chlorotoxin's properties and targets.
- Analysis of chlorotoxin's binding affinity and anti-angiogenic effects.
Main Results:
- Chlorotoxin selectively binds to GBM cells (∼100% positivity) with no cross-reactivity to normal brain tissue.
- Identified molecular targets include voltage-gated chloride channels, Annexin-2, and Matrix Metalloproteinase-2 (MMP-2), with MMP-2 showing significant anti-neoplastic potential.
Conclusions:
- Chlorotoxin is a promising tumor-targeting peptide for GBM due to its specificity and small size, suitable for intracranial delivery.
- Potential applications include targeted chemotherapy, immunotherapy, intraoperative imaging, and nano-vector technologies for GBM treatment.
